To the Editor: The Selenium and Vitamin E Cancer Prevention Trial (SELECT) by Dr Lippman and colleagues1 reported that selenium or vitamin E alone or in combination did not prevent prostate cancer. The negative results of this trial confirm the outcomes in the Nutritional Prevention of Cancer (NPC) Trial for those participants with the highest baseline plasma selenium concentration prior to supplementation with selenized yeast.2 The conclusion from both NPC and SELECT should be that daily selenium supplementation will not benefit all persons. Cancer risk reduction with selenium should be expected only in men with low or suboptimal levels prior to supplementation.
A U-shaped dose-response relationship between selenium intake and cancer risk, as suggested by studies in dogs,3 is consistent with the results of SELECT and NPC. At baseline, the average participant in SELECT had selenium status within the trough of the U-shaped curve, ie, not low or suboptimal. After supplementation with 200 μg per day of selenium as selenomethionine, the average SELECT participant achieved selenium levels that far exceeded the high postsupplementation values of men in NPC in the highest baseline-selenium tertile. Those NPC participants experienced no prostate-cancer risk reduction and an almost 3-fold increased incidence of diabetes.2 ,4 In SELECT, there was no reduction in prostate-cancer risk and a statistically nonsignificant increased diabetes incidence. We therefore consider the results of SELECT and NPC to be consistent, not contradictory.
We believe that it is time to move beyond the belief that any particular agent administered at the same dose to all participants will benefit the overall population and instead attempt to individualize cancer prevention.3 Subsets of individuals should be identified who are more likely to benefit from supplementation, such as persons with low selenium concentrations or perhaps those with the selenoprotein-P genotype that is associated with prostate-cancer risk.5 This stance is distinct from claiming knowledge of which types of cancer will or will not be prevented by selenium.
Financial Disclosures: Dr Rayman reported receiving grant support from Wassen International, a manufacturer of nutritional supplements, including selenium. Dr Waters reported that he is director of the Murphy Cancer Foundation, a not-for-profit research institute that, in collaboration with Bostwick Laboratories, markets a toenail test for selenium. Dr Waters reported that he has no financial interest in Bostwick Laboratories and no financial relationships with any manufacturers of selenium supplements. Dr Combs reported no disclosures.
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Instructions
Comments are moderated and will appear on the site at the discretion of the Journal of American Medical Association editors. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest* Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Customize your page view by dragging & repositioning the boxes below.
and access these and other features:
Register Now
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.